Bioproduction in cell therapy: the case of CAR-T cells by the MEARY platform
Pr Jérôme LARGHERO, Stéphanie DECOOPMAN et Pr Philippe MENASCHÉ
France ranks second in Europe for the production of biological drugs, which account for a growing share of the global pharmaceuticals market. Preserving France's leadership in this field means reconciling ethical, technological, financial and regulatory issues.
France has a number of strengths in this highly competitive sector, but it still needs to develop an industry to ensure the transition between R&D work, clinical trials and the industrialization phase, and to expand its production capacities. The MEARY Center, dedicated to the manufacture of cell and gene therapy drugs, on the site of the Saint-Louis Hospital of the Assistance Publique - Hôpitaux de Paris, can play a decisive role in transforming the excellence, know-how and disruptive technologies of our researchers and start-ups into building blocks for innovation and industrialization.
Since its creation in 2020, the MEARY Center has aimed to facilitate the transition to the clinic by offering a simplified process. It has already developed numerous academic projects and entered into several industrial partnerships. Through this project, the AP-HP is helping to structure and animate the medical and scientific offering around the bio-production of advanced therapy drugs, as part of its overall innovation strategy.
Read the rest of the article here.
